ReviewBiochemical pharmacology2021
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
Review in Biochemical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.Asian journal of andrologyPooled it
- Article
- Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- The potential role of brain renin-angiotensin system in the neuropathology of Parkinson disease: Friend, foe or turncoat?Journal of cellular and molecular medicine · 2024Review
- The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS).Molecular and cellular biochemistry · 2024Review
- Role of brain renin-angiotensin system in depression: A new perspective.CNS neuroscience & therapeutics · 2024Review
- LIPS and PaOMediators of inflammation · 2024Observational
- Sildenafil and depression: True or false prophecy.CNS neuroscience & therapeutics · 2023Article
- NHC-catalyzed enantioselective access to β-cyano carboxylic esters via in situ substrate alternation and release.Nature communications · 2023Article
- Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19.Scientific reports · 2023Article
- Mixed storm in SARS-CoV-2 infection: A narrative review and new term in the Covid-19 era.Immunity, inflammation and disease · 2023Review
- The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread.Immunity, inflammation and disease · 2023Review
- Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.Inflammopharmacology · 2022Review
- The role of berberine in Covid-19: potential adjunct therapy.Inflammopharmacology · 2022Review
- Ginkgo biloba in the management of the COVID-19 severity.Archiv der Pharmazie · 2022Review
- The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches.International journal of molecular sciences · 2022Review
- Hemolytic anemia in COVID-19.Annals of hematology · 2022Review
- Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.International immunopharmacology · 2022Review
- Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke.Biomedicines · 2022Review
- An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin-converting enzyme 2 (ACE2) is the binding-site and entry-point for SARS-CoV-2 in human and highly expressed in the lung. Cigarette smoking (CS) is the leading cause of pulmonary and cardiovascular diseases. Chronic CS leads to upregulation of bronchial ACE2 inducing a high vulnerability in COVID-19 smoker patients. Interestingly, CS-induced dysregulation of pulmonary renin-angiotensin system (RAS) in part contributing into the potential pathogenesis COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). Since, CS-mediated ACE2 activations is not the main pathway for increasing the risk of COVID-19, it appeared that AngII/AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.